Status:

COMPLETED

A Safety and Efficacy Study of Corneal Injection for Endothelial Dysfunction Using Human Corneal Endothelial Cell Therapy in Subjects With Corneal Edema Secondary to Endothelial Dysfunction

Lead Sponsor:

Aurion Biotech

Conditions:

Corneal Edema

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

The purpose of this study is to assess the safety of a fixed dose of human corneal endothelial cells when administered with varying concentrations of Rho kinase inhibitor (Y-27632) in patients with co...

Eligibility Criteria

Inclusion

  • Key
  • Must have given written informed consent (signed and dated by subject or legal guardian), and any authorizations required by local law and be able to comply with all study requirements
  • Clinical diagnosis of corneal edema secondary to endothelial dysfunction
  • Best Corrected Visual Acuity (BCVA) no worse than 20/800 ETDRS (1.6 LogMAR) or better than 20/63 (0.5 LogMAR) in the study eye
  • Key

Exclusion

  • Keratoconus or other conditions of corneal thinning/ectasia
  • Progressive stromal or anterior corneal dystrophies
  • Pre-operative corneal epithelial, sub-epithelial or stromal staining, scarring or other opacity that is paracentral/central and visually significant, but not suspected to be secondary to corneal endothelial disease with the potential to improve from treatment with HCEC-1
  • Prior ophthalmic surgery including cataract surgery except as noted above in Inclusion Criterion #4, corneal transplantation, glaucoma (MIGS, iridectomy, trabeculectomy, valve), or vitreo-retinal surgery, aphakia, anterior chamber-IOL or iris claw IOL, multifocal IOL.
  • Relative Afferent Pupillary Defect (RAPD) in the study eye
  • Uncontrolled glaucoma or an IOP greater than 24 mmHg that is not controlled with topical beta blockers alone at the time of the Screening Visit.

Key Trial Info

Start Date :

March 24 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 9 2023

Estimated Enrollment :

22 Patients enrolled

Trial Details

Trial ID

NCT05309135

Start Date

March 24 2022

End Date

March 9 2023

Last Update

August 19 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Site

San Salvador, El Salvador